Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as GBX 5 and last traded at GBX 5, with a volume of 140799 shares changing hands. The stock had previously closed at GBX 5.25.
Allergy Therapeutics Trading Up 4.8%
The business has a 50-day moving average price of GBX 6.98 and a two-hundred day moving average price of GBX 9.36. The stock has a market capitalization of £348.29 million, a P/E ratio of -5.67, a P/E/G ratio of -30.70 and a beta of 0.87. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}